

June 1, 2021



Medexus to Present at The LD Micro Virtual Invitational XI on June 8th

TORONTO and CHICAGO and MONTREAL, June 01, 2021 (GLOBE NEWSWIRE) -- [Medexus Pharmaceuticals Inc.](#) (the “Company” or “Medexus”) ([TSXV: MDP](#), [OTCQX: MEDXF](#)), today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021.

Ken d’Entremont, Chief Executive Officer of Medexus, and Roland Boivin, Chief Financial Officer of Medexus, are scheduled to host a virtual presentation to investors during the event as follows:

2021 LD Micro Invitational XI

Date: Tuesday, June 8, 2021

Time: 12:30 p.m. EST – Track 1

Webcast: [Sequire | Virtual Events \(mysequire.com\)](#)

For more information on the LD Micro Invitational XI, or to register for the event, please visit <https://ldmicrojune2021.mysequire.com>.

About Medexus Pharmaceuticals Inc.

Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action.

MEDEXUS CONTACTS:

Ken d’Entremont, Chief Executive Officer
Medexus Pharmaceuticals Inc.

Tel.: 905-676-0003

E-mail: ken.dentremont@medexus.com

Roland Boivin, Chief Financial Officer

Medexus Pharmaceuticals Inc.
Tel.: 514-762-2626 ext. 202
E-mail: roland.boivin@medexus.com

Investor Relations (U.S.):

Crescendo Communications, LLC
Tel: +1-212-671-1020
Email: mdp@crescendo-ir.com

Investor Relations (Canada):

Tina Byers
Adelaide Capital
Tel: 905-330-3275
E-mail: tina@adcap.ca



Source: Medexus Pharmaceuticals Inc